{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:43:56Z","timestamp":1761101036463,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"vor","delay-in-days":1642,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NIH, CRUK and MRC"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.bbmt.2010.10.011","type":"journal-article","created":{"date-parts":[[2010,12,31]],"date-time":"2010-12-31T04:48:08Z","timestamp":1293770888000},"page":"S63-S70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"S","title":["Stem Cell Transplantation for Indolent Lymphoma and Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"17","author":[{"given":"John G.","family":"Gribben","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chitra","family":"Hosing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2010.10.011_bib1","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1182\/blood.V77.11.2524.2524","article-title":"Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin\u2019s lymphoma","volume":"77","author":"Freedman","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib2","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma","volume":"94","author":"Freedman","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2000.18.3.527","article-title":"High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up","volume":"18","author":"Apostolidis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.10.011_bib4","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJM199111283252201","article-title":"Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma","volume":"325","author":"Gribben","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.10.011_bib5","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood.V81.12.3449.3449","article-title":"Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma","volume":"81","author":"Gribben","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib6","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2004.10.054","article-title":"Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.10.011_bib7","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/sj.leu.2404346","article-title":"Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial","volume":"20","author":"Ladetto","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.10.011_bib8","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1182\/blood.V83.12.3437.3437","article-title":"Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress?","volume":"83","author":"Stone","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib9","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood.V88.7.2780.bloodjournal8872780","article-title":"High dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission","volume":"88","author":"Freedman","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib10","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.V97.2.404","article-title":"High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial","volume":"97","author":"Horning","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib11","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib12","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib13","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib14","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib15","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.10.011_bib16","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2005-05-1778","article-title":"Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib17","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1182\/blood-2003-05-1549","article-title":"The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status","volume":"103","author":"Dreger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib18","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2005-05-1778","article-title":"Autologous and allogeneic stem cell transplantation for poor risk chronic lymphocytic leukemia","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2004-01-0298","article-title":"Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses","volume":"105","author":"Milligan","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib20","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.bmt.1705375","article-title":"Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience","volume":"37","author":"Jantunen","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.011_bib21","first-page":"1832","article-title":"Allogeneic bone marrow transplantation for low-grade lymphoma","volume":"92","author":"van Besien","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib22","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.011_bib23","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.011_bib24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/0003-4819-124-3-199602010-00005","article-title":"HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for blood and marrow transplantation and the International bone marrow transplant registry","volume":"124","author":"Michallet","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2010.10.011_bib25","doi-asserted-by":"crossref","first-page":"780","DOI":"10.7326\/0003-4819-125-9-199611010-00026","article-title":"Allogenic bone marrow transplantation in chronic lymphocytic leukemia","volume":"125","author":"Khouri","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2010.10.011_bib26","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/sj.bmt.1703548","article-title":"Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia","volume":"29","author":"Doney","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.011_bib27","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib28","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1046\/j.1365-2141.1997.272673.x","article-title":"Allogeneic blood\u00a0or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease","volume":"97","author":"Khouri","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.10.011_bib29","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin\u2019s lymphoma","volume":"26","author":"Rezvani","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.10.011_bib31","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3324\/haematol.10924","article-title":"Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)","volume":"92","author":"Vigouroux","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2010.10.011_bib32","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib33","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"26","author":"Sorror","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.10.011_bib34","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.leu.2402905","article-title":"Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning","volume":"17","author":"Dreger","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.10.011_bib35","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bbmt.2006.06.004","article-title":"Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia","volume":"12","author":"Brown","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.011_bib36","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2005-08-3372","article-title":"Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study","volume":"107","author":"Delgado","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib37","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/asheducation-2006.1.390","article-title":"Reduced-intensity regimens in allogeneic stem-cell transplantation for non-Hodgkin lymphoma and chronic lymphocytic leukemia","author":"Khouri","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2010.10.011_bib38","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.2003.12.011","article-title":"Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group","volume":"21","author":"Schetelig","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.10.011_bib39","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1182\/blood-2005-09-3634","article-title":"Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia","volume":"107","author":"Moreno","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib40","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/blood-2009-11-255182","article-title":"Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma","volume":"115","author":"Lambert","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib41","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/sj.leu.2403745","article-title":"Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis","volume":"19","author":"Dreger","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.10.011_bib42","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1200\/JCO.2008.16.2982","article-title":"Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation Analysis","volume":"26","author":"Schetelig","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.10.011_bib43","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.10.011_bib44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.13574","article-title":"Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols","volume":"94","author":"de Jong","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2010.10.011_bib45","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2006.06.4642","article-title":"Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.10.011_bib46","doi-asserted-by":"crossref","first-page":"6421","DOI":"10.1200\/JCO.2005.06.004","article-title":"Immunotherapy for non-Hodgkin\u2019s lymphoma: monoclonal antibodies and vaccines","volume":"23","author":"Maloney","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.10.011_bib47","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/01.cco.0000174040.52427.83","article-title":"Current status of therapeutic vaccines for non-Hodgkin\u2019s lymphoma","volume":"17","author":"Hurvitz","year":"2005","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.bbmt.2010.10.011_bib48","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2008-10-185280","article-title":"Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a \u201cvaccinal effect\u201d of rituximab","volume":"113","author":"Hilchey","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib49","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI31202","article-title":"Tregs and rethinking cancer immunotherapy","volume":"117","author":"Curiel","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bbmt.2010.10.011_bib50","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2008-12-172825","article-title":"Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB","volume":"113","author":"Hagemann","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib51","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI24176","article-title":"Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells","volume":"115","author":"Gorgun","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bbmt.2010.10.011_bib52","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.bbmt.2010.10.011_bib53","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib54","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1182\/blood-2009-11-253260","article-title":"Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting micro-environment","volume":"115","author":"Clear","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.011_bib55","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/bmt.2009.289","article-title":"CD3(+) and\/or CD14(+) depletion from cord blood mononuclear cells before ex vivo expansion culture improves total nucleated cell and CD34(+) cell yields","volume":"45","author":"Yang","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.011_bib56","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/CJI.0b013e3181e475e9","article-title":"Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with il-2 exvivo expansion","volume":"33","author":"Xing","year":"2010","journal-title":"J Immunother"},{"key":"10.1016\/j.bbmt.2010.10.011_bib57","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-05-283309","article-title":"The B-cell tumor associated antigen ROR1 can be targeted with T-cells modified to express a ROR1-specific chimeric antigen receptor","author":"Hudecek","year":"2010","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110004490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110004490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:38:26Z","timestamp":1761057506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879110004490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S1083879110004490"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.10.011","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stem Cell Transplantation for Indolent Lymphoma and Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}